NO170889C - Fremgangsmaate for fremstilling av et stabilt krystallinskdi- eller trihydrat av 7beta-((z)-2-(2-aminotiazol-4-yl)-4-karboksybut-2-enoylamino)-3-cefem-4-karboksylsyre - Google Patents

Fremgangsmaate for fremstilling av et stabilt krystallinskdi- eller trihydrat av 7beta-((z)-2-(2-aminotiazol-4-yl)-4-karboksybut-2-enoylamino)-3-cefem-4-karboksylsyre

Info

Publication number
NO170889C
NO170889C NO872729A NO872729A NO170889C NO 170889 C NO170889 C NO 170889C NO 872729 A NO872729 A NO 872729A NO 872729 A NO872729 A NO 872729A NO 170889 C NO170889 C NO 170889C
Authority
NO
Norway
Prior art keywords
aminotiazol
carboxybut
7beta
enoylamino
cefem
Prior art date
Application number
NO872729A
Other languages
English (en)
Norwegian (no)
Other versions
NO872729L (no
NO170889B (no
NO872729D0 (no
Inventor
Yoshio Hamashima
Kyoji Minami
Kyozo Kawata
Teruo Sakamoto
Toyohiko Takeda
Yusuke Suzuki
Masanori Tujikawa
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP61156954A external-priority patent/JP2544113B2/ja
Priority claimed from JP21626086A external-priority patent/JPH0717651B2/ja
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NO872729D0 publication Critical patent/NO872729D0/no
Publication of NO872729L publication Critical patent/NO872729L/no
Priority to NO911964A priority Critical patent/NO303264B1/no
Priority to NO921401A priority patent/NO921401D0/no
Publication of NO170889B publication Critical patent/NO170889B/no
Publication of NO170889C publication Critical patent/NO170889C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
NO872729A 1986-07-02 1987-06-30 Fremgangsmaate for fremstilling av et stabilt krystallinskdi- eller trihydrat av 7beta-((z)-2-(2-aminotiazol-4-yl)-4-karboksybut-2-enoylamino)-3-cefem-4-karboksylsyre NO170889C (no)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NO911964A NO303264B1 (no) 1986-07-02 1991-05-22 FremgangsmÕte for fremstilling av et stabilt kapselpreparat
NO921401A NO921401D0 (no) 1986-07-02 1992-04-09 Fremgansmaate for fremstilling av et stabilt kapselpreparat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61156954A JP2544113B2 (ja) 1986-07-02 1986-07-02 安定なカプセル製剤
JP21626086A JPH0717651B2 (ja) 1986-09-12 1986-09-12 経口投与用セフアロスポリン水和物結晶

Publications (4)

Publication Number Publication Date
NO872729D0 NO872729D0 (no) 1987-06-30
NO872729L NO872729L (no) 1988-01-04
NO170889B NO170889B (no) 1992-09-14
NO170889C true NO170889C (no) 1992-12-23

Family

ID=26484565

Family Applications (1)

Application Number Title Priority Date Filing Date
NO872729A NO170889C (no) 1986-07-02 1987-06-30 Fremgangsmaate for fremstilling av et stabilt krystallinskdi- eller trihydrat av 7beta-((z)-2-(2-aminotiazol-4-yl)-4-karboksybut-2-enoylamino)-3-cefem-4-karboksylsyre

Country Status (27)

Country Link
US (2) US4812561A (enExample)
KR (1) KR950005302B1 (enExample)
CN (1) CN1015106B (enExample)
AR (1) AR243893A1 (enExample)
AT (1) AT392472B (enExample)
AU (1) AU594167B2 (enExample)
BE (1) BE1001691A4 (enExample)
CA (1) CA1283405C (enExample)
CH (1) CH672788A5 (enExample)
DE (1) DE3721913A1 (enExample)
DK (1) DK161080C (enExample)
ES (2) ES2004952A6 (enExample)
FI (1) FI89052C (enExample)
FR (1) FR2601014B1 (enExample)
GB (1) GB2192183B (enExample)
GR (1) GR871014B (enExample)
HK (1) HK47893A (enExample)
HU (1) HU200777B (enExample)
IE (1) IE59613B1 (enExample)
IL (1) IL83059A (enExample)
IT (1) IT1211469B (enExample)
NL (1) NL193136C (enExample)
NO (1) NO170889C (enExample)
NZ (1) NZ220764A (enExample)
PL (1) PL159180B1 (enExample)
RU (1) RU1829932C (enExample)
SE (1) SE466257B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089270A (en) * 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
AU674516B2 (en) * 1992-04-30 1997-01-02 Schering Corporation Stable hydrated cephalosporin dry powder for oral suspension formulation
CN1307211C (zh) * 1998-10-27 2007-03-28 伊斯曼化学公司 烯烃聚合方法,新型聚乙烯以及由其制造的薄膜和制品
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AT412213B (de) * 2000-05-30 2004-11-25 Sandoz Ag Verfahren zur trocknung von amoxicillin oder amoxicillin-hältigen, oralen, festen pharmazeutischen zusammensetzungen unter verwendung eines gases mit einer definierten gasfeuchte
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
CA2533358C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533292C (en) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528189A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
EP1771158A4 (en) * 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSE DISTRIBUTION
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
CA2629244C (en) 2005-11-11 2014-08-05 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
MX2009006878A (es) * 2006-12-22 2009-07-07 Schering Corp Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
US8268803B2 (en) 2006-12-22 2012-09-18 Merck Sharp & Dohme Corp. 5, 6-ring annulated indole derivatives and use thereof
KR20090094154A (ko) 2006-12-22 2009-09-03 쉐링 코포레이션 Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
TW200924751A (en) * 2007-08-29 2009-06-16 Schering Corp 2,3-substituted indole derivatives and methods of use thereof
KR20100065167A (ko) 2007-08-29 2010-06-15 쉐링 코포레이션 바이러스 감염 치료용 2,3-치환된 아자인돌 유도체
CN101821252A (zh) * 2007-08-29 2010-09-01 先灵公司 取代的吲哚衍生物及其使用方法
MX2010005355A (es) * 2007-11-16 2010-06-02 Schering Corp Derivados de indol sustituidos con 3-aminosulfonilo y metodos de uso de los mismos.
US8765757B2 (en) * 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
MX2010013630A (es) * 2008-06-13 2010-12-21 Schering Corp Derivados triciclicos de indol y metodos de uso de los mismos.
WO2010022126A1 (en) 2008-08-20 2010-02-25 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282574B2 (en) 2008-08-20 2014-08-21 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5674661B2 (ja) 2008-08-20 2015-02-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
DK2451445T3 (da) 2009-07-06 2019-06-24 Boehringer Ingelheim Int Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
EP2516430B1 (en) 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
BR112012022125A2 (pt) 2010-03-09 2016-11-01 Merck Sharp & Dhme Corp composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
EP2566449B1 (en) 2010-05-04 2014-10-08 Mahmut Bilgic Pharmaceutical compositions comprising ceftibuten
JP2013541499A (ja) 2010-07-26 2013-11-14 メルク・シャープ・エンド・ドーム・コーポレイション 置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法
AU2011314168A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
EA201391519A1 (ru) 2011-04-13 2014-03-31 Мерк Шарп И Доум Корп. 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
WO2013151518A1 (en) * 2012-04-04 2013-10-10 Mahmut Bilgic Capsule formulations comprising ceftibuten
EP2815743A1 (en) 2013-06-21 2014-12-24 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten formulations
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103948932B (zh) * 2014-04-17 2016-03-16 海南日中天制药有限公司 一种头孢克肟组合物及其制备方法
EP3031450A1 (en) 2014-12-12 2016-06-15 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten capsule compositions
US11117909B2 (en) 2016-05-13 2021-09-14 Aeromics, Inc. Crystals
CN106397454B (zh) * 2016-08-30 2018-08-24 山东罗欣药业集团股份有限公司 一种抗感染药物头孢布烯晶型化合物及其组合物
CN106432270A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106397457A (zh) * 2016-09-21 2017-02-15 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
CN106432272A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106432271A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
JP2024524372A (ja) * 2021-07-01 2024-07-05 キューペックス バイオファーマ， インコーポレイテッド セフチブテンの結晶形態

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819620A (en) * 1972-06-01 1974-06-25 Squibb & Sons Inc 7-(d-alpha-amino-1,4-cyclohexadien-1-ylacet-amido)desacetoxycephalosporanic acid dihydrate
JPS5726692A (en) * 1980-07-22 1982-02-12 Fujisawa Pharmaceut Co Ltd Preparation of stable crystal of salt of ceftizoxime
DE3037997A1 (de) * 1980-10-08 1982-05-13 Bayer Ag (beta) -lactamantibiotika, verfahren zu deren herstellung sowie sie enthaltende mittel
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
AU575854B2 (en) * 1983-10-04 1988-08-11 Shionogi & Co., Ltd. 7beta-(carboxyalkenamido) cephalosporins
AU580855B2 (en) * 1985-03-29 1989-02-02 Shionogi & Co., Ltd. Alkeneamidocephalosporin esters

Also Published As

Publication number Publication date
KR950005302B1 (ko) 1995-05-23
GB2192183A (en) 1988-01-06
DK336487D0 (da) 1987-06-30
AT392472B (de) 1991-04-10
ATA165887A (de) 1990-09-15
FI89052B (fi) 1993-04-30
AU7504087A (en) 1988-01-07
NL193136B (nl) 1998-08-03
IE59613B1 (en) 1994-03-09
AU594167B2 (en) 1990-03-01
PL159180B1 (pl) 1992-11-30
FI89052C (fi) 1993-08-10
HU200777B (en) 1990-08-28
US4812561A (en) 1989-03-14
BE1001691A4 (fr) 1990-02-13
GB2192183B (en) 1990-05-16
CN87105009A (zh) 1988-03-23
FI872903L (fi) 1988-01-03
US4933443A (en) 1990-06-12
KR880001670A (ko) 1988-04-26
ES2008759A6 (es) 1989-08-01
IE871738L (en) 1988-01-02
IL83059A0 (en) 1987-12-31
FR2601014B1 (fr) 1990-09-14
RU1829932C (ru) 1993-07-23
HUT44257A (en) 1988-02-29
DE3721913A1 (de) 1988-01-07
SE8702705D0 (sv) 1987-06-30
ES2004952A6 (es) 1989-02-16
CH672788A5 (enExample) 1989-12-29
FR2601014A1 (fr) 1988-01-08
NL193136C (nl) 1998-12-04
GR871014B (en) 1987-11-02
PL266567A1 (en) 1988-07-21
NZ220764A (en) 1989-09-27
DK336487A (da) 1988-01-03
FI872903A0 (fi) 1987-07-01
DK161080B (da) 1991-05-27
AR243893A1 (es) 1993-09-30
IL83059A (en) 1992-03-29
SE466257B (sv) 1992-01-20
IT8767566A0 (it) 1987-07-01
NL8701507A (nl) 1988-02-01
IT1211469B (it) 1989-11-03
HK47893A (en) 1993-05-27
NO872729L (no) 1988-01-04
CA1283405C (en) 1991-04-23
CN1015106B (zh) 1991-12-18
GB8715064D0 (en) 1987-08-05
NO170889B (no) 1992-09-14
NO872729D0 (no) 1987-06-30
DK161080C (da) 1991-11-11
SE8702705L (sv) 1988-01-03

Similar Documents

Publication Publication Date Title
NO170889C (no) Fremgangsmaate for fremstilling av et stabilt krystallinskdi- eller trihydrat av 7beta-((z)-2-(2-aminotiazol-4-yl)-4-karboksybut-2-enoylamino)-3-cefem-4-karboksylsyre
NO170079C (no) Fremgangsmaate for fremstilling av et krystallinsk torasemid
NO171781C (no) Fremgangsmaate for fremstilling av en selvbaerende keramiskstruktur
SG59692G (en) Salts of amlodipine
NO170516C (no) Fremgangsmaate for fremstilling av en formulering av beclomethasondipropionat
PT86309A (en) Process for the preparation of substituted basic 2-aminotetralins
PT86934A (pt) Process for the preparation of a thiazepine compound
IL87491A0 (en) Preparation of sulfonylurea salts
NO172447C (no) Fremgangsmaate for fremstilling av b-avermectiner
PT85476A (en) Process for preparing a substituted phenyl butenamide derivatives
NO173786C (no) Fremgangsmaate for fremstilling av en osseinhydroksyapatittforbindelse (OHC)
PT87854A (pt) Process for the preparation of thio-urea derivatives
GB8721294D0 (en) Salts of organogermanium compounds
GB8713987D0 (en) Medicarpin derivatives & analogs
PT84268A (en) Process for the preparation of cyanoethanimidamide compounds
AU8161487A (en) Saccharine salts of substituted hydroxypropylamines
AU599740B2 (en) Cooler of a substance
YU45030B (en) Process for preparing crystalline cimetidine
GB8705472D0 (en) Preparation of heterocyclic compounds
IT8947902A0 (it) Procedimento per preparare composti antibiotici
GB8801577D0 (en) Ryfamycin derivatives salts
GB8606308D0 (en) Elements for construction of racks trellisworks
GB8630323D0 (en) X-ray studies of crystalline matter
GB8603549D0 (en) Phosphonic acid derivatives
ZA876135B (en) Pyridinio compounds

Legal Events

Date Code Title Description
MK1K Patent expired